10/29/2020

speaker
Chris
Executive (likely CEO) of Avello

very interesting and would in principle support potentially going to later stage clinical trials. Obviously, if we see something at a lower level, then it potentially is still interesting in terms of supporting activation of systemic immunity consistent with what I've just described. So that's what we're waiting for there. Let me pass over to Mark who can talk about maybe I'd suggest Mark do the EV response first and then you can respond on neuro-inflam and if there's anything you don't get to, Duncan can talk about neuro-inflam. Sure. Hello, Chris.

speaker
Mark
Scientific/Technical Representative

Mark here. The drug product is a natural component of the fermentation. It's the part we normally throw away because the extracellular vesicles are shed from the bacteria into the medium. Rather than harvesting the cells, We harvest the medium and we purify it by a mixture of centrifugation and filtration. It's fairly straightforward. I'm going to answer your questions about purity and content in a regulatory context because I suspect that's part of what you have in mind in asking it. And we have discussed these questions with regulatory authorities both in the U.S. and in the U.K. with very positive outcomes because they recognized that the extracellular vesicles were part of or likely to be part of the types of products that we are already using in the clinic as whole microbes. So actually the preclinical development requirements we have for EVs at the moment don't look to be any different for the microbes, which is hugely beneficial because as you'll recall, we haven't had to do preclinical toxicology testing. And because these are natural products, orally delivered, the requirements for purity are completely different than they would be, for instance, if we were making a mammalian exosome and trying to inject it intravenously or by some other parenteral route. So there's a permissive path for these things that are the same as for the microbes. One other comment about the drug product itself, if we look at dose yield per liter of fermentation, which is where essentially the cost and scale issue will come, it's pretty similar for the EVs as it is to the whole microbes. It actually may be a little bit higher. So we haven't changed our manufacturing scale requirements. It just changes the downstream processing a bit. And then content. So the EVs basically grab parts of the macromolecular content of the parent bacterium. It's not a one-for-one matching, and we're doing a lot of omics at the moment to try and look at that. But, of course, we get a hairball of data showing that some bacteria some proteins are more highly represented in the EV versus the bacterium and the other way around. And we're looking at glycol lipids and, and, uh, and the rest. Um, and, uh, you know, the, uh, the differences we're seeing in the efficacy, which you'll see, uh, in the city poster shortly between the whole microbe and the EV, um, maybe due to differences in content. I suspect it's more to do with the pharmacodynamics of the EV and its ability to get to the target. So that's where we are with that. I hope that answers your question there.

speaker
Unidentified Analyst
Conference Call Participant

Yeah, and I'm sorry, Mark, but maybe just a very brief clarification. And it's basically, it's a lyophilized product in a capsule. Is that the dosage form? Yes, sorry.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-